Outcome notifications
Outcome notifications of regular abstracts are expected to be made available to first authors and submitters by early-March 2027.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by mid-April 2027.
Detailed instructions for the preparation of slide presentations and/or posters will be made available by early-March 2027 in the section “Information for Presenters”.
Abstract presenter registration
The presenting author or the designated replacement presenter must be registered by 21 April 2027. Should the Presenter (or designated replacement presenter) not be registered by the given deadline, the abstract will be excluded from presentation in the ESMO Breast Cancer 2027 programme and removed from the online programme and publication in the ESMO Breast Cancer 2027 Abstract Book.
Abstract submission categories
- Biomarkers and translational research and precision medicine
- Early breast cancer: Surgery and radiotherapy
- Early breast cancer: Systemic treatments
- Early detection, hereditary breast cancer and prevention
- Metastatic breast cancer
- Supportive care and survivorship
- Miscellaneous
Late-breaking abstracts
Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes.
The final late-breaking abstract deadline of 6 April 2027 is under no circumstances to be considered as an extension of the general submission deadline (2 February 2027).
Trial in Progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO Breast Cancer 2027.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Presentation and publication of accepted abstracts
The Breast Cancer 2027 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Rapid Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Paper poster presentation for review and discussion onsite. Presenting authors must attend the Congress in person to represent their work. Preparation of an e-Poster file is also mandatory for inclusion in the Congress Virtual Platform and onsite digital screens.
- e-Poster - Electronic poster in PDF format for inclusion in the Congress Virtual Platform. Presenting authors of e-Posters are not required to attend the Congress in person to represent their work. Paper posters are not to be prepared, and poster boards will not be provided.
All accepted abstracts, including Late-breaking, will be published online in the ESMO Breast Cancer 2027 Abstract Book, a supplement to the official ESMO journal, ESMO Open.
Publication schedule of accepted abstracts
Abstracts accepted for presentation during the ESMO Breast Cancer 2027 will be released online according to a schedule which will be available on the ESMO website in due course.
ESMO Merit Award
A restricted number of ESMO Merit Award to the ESMO Breast Cancer 2027 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Breast Cancer 2027 Scientific Committee on a competitive basis from among the accepted abstracts.
